StemCells (STEM) completes dosing of HuCNS-SC in PMD Trial
February 17th, 2011
No comments
STEM’s 4th and final patient in its P I clinical trial in Pelizaeus-Merzbacher Disease (PMD) has been transplanted Read more…
Archive
Posts Tagged ‘STEM’
First Neural Stem Cell Trial in Spinal Cord Injury, StemCells (STEM)
December 7th, 2010
No comments
STEM has received authorization to initiate a Phase I/II clinical trial of the HuCNS-SC(R) product candidate (purified human neural stem cells) in chronic spinal cord injury Read more…
Proprietary Human Cell Detection Antibodies Launch, StemCells (STEM)
December 7th, 2010
No comments
STEM announced the launch of STEM101™, STEM121™ and STEM123™; Read more…
Categories: NASDAQ: STEM, Stem Cell Technology
Q3/10 Results, StemCells (STEM)
November 4th, 2010
No comments
STEM reported a net loss of $5.552M, or $(0.04) per share. Read more…
Categories: NASDAQ Listing Issue, NASDAQ: STEM, Q3/10 Results, Stem Cell Technology
QTDP Grant of $977,917, StemCells (STEM)
November 3rd, 2010
No comments
STEM has been awarded cash grants by the US totaling $977,917 for projects Read more…
2nd Clinical Trial in Batten Disease, StemCells (STEM)
October 29th, 2010
No comments
STEM initiated a 2nd clinical trial of its HuCNS-SC(R) product candidate (purified human neural stem cells) Read more…
Categories: Batten disease, NASDAQ: STEM, Phase Ib trial, Stem Cell Technology
Updating, StemCells (STEM)
October 11th, 2010
No comments
STEM’s lead product candidate, HuCNS-SC cells, is a highly purified composition of human neural stem cells that are expanded and stored as banks of cells. Read more…
Categories: Stem Cell Technology
Progress in Myelination Disorder Trial, StemCells (STEM)
October 8th, 2010
No comments
STEM provided an update on its ongoing Phase I clinical trial in Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder that afflicts male children. Read more…
Categories: Pelizeaus-Merzbacher Disease (PMD), Stem Cell Technology
hNSC Breakthrough in Chronic Spinal Cord Injury, StemCells (NASDAQ: STEM)
August 20th, 2010
No comments
STEM published new preclinical data demonstrating proprietary human neural stem cells to restore lost motor function in mice with chronic spinal cord injury. Read more…
Categories: Stem Cell Technology
Q2/10 Results, StemCells (STEM)
August 10th, 2010
No comments
STEM reported net loss of $4.61 M, or $0.04 per share. Read more…
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.